iData Insights

Follicular Lymphoma - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 02, 2016 15:11 IST

This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 11

Global Markets Direct Report Coverage 11

Diffuse Large B-Cell Lymphoma Overview 12

Therapeutics Development 13

Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 13

Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 14

Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 15

Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 22

Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Diffuse Large B-Cell Lymphoma - Products under Development by Companies 26

Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 34

Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 35

AbbVie Inc. 35

Acetylon Pharmaceuticals, Inc. 36

Affimed Therapeutics AG 37

Amgen Inc. 38

Aprogen, Inc. 39

Arrien Pharmaceuticals, LLC 40

Astellas Pharma Inc. 41

AstraZeneca Plc 42

Aurigene Discovery Technologies Limited 43

Bayer AG 44

BeiGene(Beijing) Co.,Ltd 45

BIND Therapeutics, Inc. 46

Biocon Limited 47

Bristol-Myers Squibb Company 48

Celgene Corporation 49

Cell>Point, L.L.C. 50

Cellular Biomedicine Group, Inc. 51

Constellation Pharmaceuticals, Inc. 52

CTI BioPharma Corp. 53

Curis, Inc. 54

Cyclacel Pharmaceuticals, Inc. 55

Eisai Co., Ltd. 56

EpiZyme, Inc. 57

Erytech Pharma SA 58

F. Hoffmann-La Roche Ltd. 59

Genentech, Inc. 60

Gilead Sciences, Inc. 61

GlaxoSmithKline Plc 62

Hutchison MediPharma Limited 63

Idera Pharmaceuticals, Inc. 64

ImmunoGen, Inc. 65

Immunomedics, Inc. 66

Immunovaccine, Inc. 67

Incyte Corporation 68

Inflection Biosciences Limited 69

Johnson & Johnson 70

Juno Therapeutics Inc. 71

Karus Therapeutics Limited 72

Karyopharm Therapeutics, Inc. 73

Kite Pharma, Inc. 74

Mabion SA 75

mAbxience S.A. 76

MedImmune, LLC 77

Medivation, Inc. 78

Merck & Co., Inc. 79

Millennium Pharmaceuticals, Inc. 80

Mirati Therapeutics Inc. 81

Mirna Therapeutics, Inc. 82

Molplex Ltd. 83

MorphoSys AG 84

Neumedicines Inc. 85

Nimbus Therapeutics, LLC 86

Nordic Nanovector ASA 87

Novartis AG 88

Ono Pharmaceutical Co., Ltd. 89

Onyx Pharmaceuticals, Inc. 90

Pfizer Inc. 91

Philogen S.p.A. 92

Portola Pharmaceuticals, Inc. 93

ProNAi Therapeutics, Inc. 94

RedHill Biopharma Ltd. 95

Redx Pharma Plc 96

Respiratorius AB 97

Rhizen Pharmaceuticals S.A. 98

Sandoz International GmbH 99

Seattle Genetics, Inc. 100

Selvita SA 101

Taiho Pharmaceutical Co., Ltd. 102

TG Therapeutics, Inc. 103

Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 104

Assessment by Monotherapy Products 104

Assessment by Combination Products 105

Assessment by Target 106

Assessment by Mechanism of Action 111

Assessment by Route of Administration 115

Assessment by Molecule Type 117

Drug Profiles 119

187Re-EC-G - Drug Profile 119

ABC-294640 - Drug Profile 120

acalabrutinib - Drug Profile 123

acalisib - Drug Profile 126

ACY-775 - Drug Profile 127

AFM-11 - Drug Profile 129

AFM-13 - Drug Profile 130

alisertib - Drug Profile 131

ARN-3236 - Drug Profile 135

ARN-3261 - Drug Profile 136

ASN-002 - Drug Profile 137

asparaginase - Drug Profile 138

atezolizumab - Drug Profile 140

azacitidine - Drug Profile 144

AZD-2811 - Drug Profile 148

AZD-3965 - Drug Profile 149

AZD-9150 - Drug Profile 151

bendamustine hydrochloride - Drug Profile 152

Betalutin - Drug Profile 155

BGB-3111 - Drug Profile 157

blinatumomab - Drug Profile 158

BLyS-gel - Drug Profile 161

BMS-986016 - Drug Profile 162

bortezomib - Drug Profile 163

brentuximab vedotin - Drug Profile 169

buparlisib hydrochloride - Drug Profile 176

BVX-20 - Drug Profile 180

carfilzomib - Drug Profile 181

CBM-C19.1 - Drug Profile 185

CBM-C20.1 - Drug Profile 186

CC-122 - Drug Profile 188

CC-223 - Drug Profile 190

Cellular Immunotherapy for Oncology - Drug Profile 191

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 192

cerdulatinib - Drug Profile 193

coltuximab ravtansine - Drug Profile 195

copanlisib hydrochloride - Drug Profile 197

CPI-0610 - Drug Profile 201

CPI-169 - Drug Profile 202

CUDC-907 - Drug Profile 203

CYC-065 - Drug Profile 205

daratumumab - Drug Profile 206

Darleukin - Drug Profile 210

denintuzumab mafodotin - Drug Profile 212

DPX-Survivac - Drug Profile 213

E-7449 - Drug Profile 217

entospletinib - Drug Profile 218

epacadostat - Drug Profile 219

everolimus - Drug Profile 221

GS-5829 - Drug Profile 227

GSK-2816126 - Drug Profile 228

HMPL-523 - Drug Profile 229

IBL-301 - Drug Profile 230

ibrutinib - Drug Profile 232

idelalisib - Drug Profile 239

IGN-002 - Drug Profile 242

imexon - Drug Profile 243

IMGN-529 - Drug Profile 245

IMO-8400 - Drug Profile 247

inebilizumab - Drug Profile 249

inebilizumab + rituximab - Drug Profile 251

inotuzumab ozogamicin - Drug Profile 252

IT-901 - Drug Profile 254

ixazomib citrate - Drug Profile 255

JCAR-014 - Drug Profile 259

JNJ-64052781 - Drug Profile 260

KA-2237 - Drug Profile 261

KTEC-19 - Drug Profile 262

lenalidomide - Drug Profile 265

mitoxantrone hydrochloride - Drug Profile 270

MK-2206 - Drug Profile 271

MK-8628 - Drug Profile 274

mocetinostat - Drug Profile 276

Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile 279

Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors - Drug Profile 280

MOR-208 - Drug Profile 281

MRX-34 - Drug Profile 283

NBD Peptide - Drug Profile 285

ND-2110 - Drug Profile 287

ND-2158 - Drug Profile 289

nivolumab - Drug Profile 291

NMIL-121 - Drug Profile 299

obinutuzumab - Drug Profile 301

ONC-201 - Drug Profile 304

pecazine - Drug Profile 307

pembrolizumab - Drug Profile 308

pidilizumab - Drug Profile 317

pixantrone dimaleate - Drug Profile 319

PNT-2258 - Drug Profile 323

polatuzumab vedotin - Drug Profile 325

PRT-060318 - Drug Profile 327

Pt-EC-G - Drug Profile 328

rituximab biosimilar - Drug Profile 329

rituximab biosimilar - Drug Profile 330

rituximab biosimilar - Drug Profile 331

rituximab biosimilar - Drug Profile 333

rituximab biosimilar - Drug Profile 334

romidepsin - Drug Profile 335

RP-6530 - Drug Profile 338

ruxolitinib phosphate - Drug Profile 339

SEL-24B489 - Drug Profile 344

selinexor - Drug Profile 345

SGN-CD70A - Drug Profile 351

SH-7129 - Drug Profile 352

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.